Carbapenem-resistant Acinetobacter baumannii (CRAB) poses a global health threat, lacking effective treatments for over 50 years. Investigators have studied and introduces tethered macrocyclic peptide (MCP) antibiotics, specifically zosurabalpin (RG6006), demonstrating potent antibacterial activity against CRAB. The MCPs inhibit the LptB2FGC complex, impeding lipopolysaccharide transport and effectively treating drug-resistant CRAB isolates in vitro and in mouse models. This novel antibiotic class suggests a promising treatment for CRAB infections, addressing current inadequacies, and identifies LptB2FGC as a viable target for antimicrobial drug development.